This investment comes with a company value uptick of 21.22%.
In the US, SpeeDx is finalizing clinical trials for their flagship product ResistancePlus MG, detecting the STI Mycoplasma genitalium (Mgen) and genetic markers linked to antibiotic resistance of the common macrolide frontline treatment.
Resistance rates in Mgen infection are steadily rising around the world, leading to difficult-to-treat infections.
Recommendations for resistance testing to better inform treatment decisions can be found in Mgen management guidelines around the world.
A recent partnership with Cepheid also saw the development of ResistancePlus MG on the GeneXpert platform (available in Australia, New Zealand, and parts of Europe), as part of their FleXible cartridge program, this product was launched late 2019 and is providing clinicians with timely information to assist management of Mgen infections and adhere to management guidelines.
Pre-clinical testing is wrapping up in preparation for commencing US-based clinical trials for ResistancePlus GC--a test to determine susceptibility of gonorrhoea infections to ciprofloxacin treatment.
This test has been granted Breakthrough Device designation by the FDA which will fast track the registration process. This will provide doctors and patients the option of using ciprofloxacin instead of ceftriaxone, one of the last remaining antibiotics available for multi-drug resistant gonorrhoea infections.
SpeeDx has developed a molecular diagnostics test portfolio, principally for infectious diseases, that provides both identification as well as therapeutic guidance capabilities.
The company is based in Australia, with offices in Austin and London, and distributors across Europe.
Northpond Ventures is a global science-driven innovation firm.
Since its founding, Northpond Ventures has risen to become among the most-active investors in the life sciences and molecular diagnostics industries and is very active in all disciplines related to healthcare and affiliated industries.
Its investments target the greatest scientists, innovators and entrepreneurs in life sciences, diagnostics, AI and machine learning, therapeutics, and affiliated sectors.
Northpond has in excess of USD 500m of committed capital, with over 20 businesses represented in its portfolio.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial